South Carolina measles outbreak surpasses 200 cases

South Carolina's Department of Public Health reported 26 new measles cases as of Jan. 6, bringing the Upstate outbreak to 211 cases total, with 194 cases in children under 18; 144 people are quarantined and seven are in isolation. Officials identified exposures at two elementary schools and public venues including a restaurant, a Best Buy and a library planetarium show; four people required hospitalization. Kindergarten two-dose MMR coverage in the state has fallen to 92.1% (from 95% in 2019-20) and the CDC says 97% of 2025 measles cases were unvaccinated, suggesting ongoing vulnerability and potential localized disruption to schools and consumer activity though limited systemic market risk.

Analysis

Market-structure: Outbreak creates a narrowly concentrated demand shock for vaccinations and point-of-care services (pharmacies, urgent care) while creating transient local headwinds to in-person retail in Spartanburg/Greenville. Expect a measurable but small revenue boost (+1–3%) to large pharmacy chains (CVS, WBA) in the next 4–12 weeks as catch-up MMR shots are administered; big-box retailers (BBY) risk single-digit weekly traffic declines in affected counties for days–weeks only.

Risk assessment: Tail risk is a broader multi-state spread (low-probability, high-impact) that would force school closures and depress regional retail spending for months; trigger thresholds are >1,000 linked cases or spread to >5 states within 30 days. Hidden dependencies include school-entry mandate enforcement and state procurement cycles that can create lumpy vaccine orders; catalysts are public-health campaign announcements, emergency funding, or court rulings on mandates.

Trade implications: Tactical winner is pharmacies/vaccine distributors (CVS, WBA, MCK) and modest long exposure to vaccine-maker Merck (MRK); tactical loser is localized retail (BBY) and possibly county-level mall landlords. Options: 1–3 month call spreads on CVS/WBA to capture near-term volume spike; short 1-month puts or small outright short on BBY if local foot-traffic/same-store sales fall >5% W/W.

Contrarian: Consensus understates durability of pharmacy revenue (vaccination visits are sticky ancillary sales) and overstates systemic retail hit—historical measles clusters produced concentrated, 4–12 week impacts. If kindergarten MMR coverage falls below 90% statewide, re-rate assumptions and scale healthcare longs; if coverage rebounds, unwind within 3 months.

Key Decisions for Investors

• Establish a 1–2% portfolio position split between CVS (CVS) and Walgreens (WBA) within 7–14 days using 3-month call spreads (buy ATM, sell +10–15% strike) to capture a likely 1–3% bump in vaccination revenue; trim or exit after 3–6 months or if state case counts decline >50% W/W for two consecutive weeks.
• Initiate a tactical 0.5% short on Best Buy (BBY) using 1-month puts sized to a 0.5% portfolio risk if same-store sales in Spartanburg/Greenville counties show >5% W/W decline or if two local schools close; cover if impact is contained within 2 weeks or SS Sells stabilize.
• Buy a small 0.5–1% speculative position in Merck (MRK) via 6-month calls if cases spread beyond 5 counties or exceed 500 linked cases within 30 days, target 20–30% upside from increased public/state vaccine procurement; stop-loss if no procurement announcements within 60 days.
• Reallocate 1–2% from consumer discretionary to healthcare logistics/distribution (McKesson MCK or Cardinal CAH) over next 2–6 weeks to capture lumpy public-health distribution volumes; reverse allocation if weekly vaccine order volumes normalize for 4 consecutive weeks.